Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Med.

Sec. Dermatology

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1657952

IL-5, IL-31 and Systemic Immune-Inflammation Index as Biomarkers Predicting Severity and Progression in Bullous Pemphigoid

Provisionally accepted
Yanyu  ZhangYanyu Zhang1Xia  LiuXia Liu1Lili  HouLili Hou1Yan  ZhaoYan Zhao1Jiaxuan  HaoJiaxuan Hao1Na  ZhangNa Zhang1Jing  TianJing Tian1Xiaoqing  LiXiaoqing Li1Zhiyu  LiuZhiyu Liu1Hongwei  ZhouHongwei Zhou1Chunyang  XuChunyang Xu2Yuan  RenYuan Ren1Zhou  HaizhouZhou Haizhou1*
  • 1First Affiliated Hospital of Harbin Medical University, Harbin, China
  • 2Second Affiliated Hospital of Harbin Medical University, Harbin, China

The final, formatted version of the article will be published soon.

Introduction Inflammatory mechanisms assume a pivotal role in bullous pemphigoid (BP). IL-31, IL-5, and the systemic immunoinflammatory index (SII) are emerging markers of inflammatory activity, but their associations with BP severity remain unclear. This investigation sought to investigate the correlation of the three aforementioned indicators with BP disease severity to determine their potential application in predicting BP severity. Methods This study enrolled 83 BP patients and 50 healthy controls (HC). Patients were stratified into mild-moderate (MM, n=23) and severe (Sev., n=60) groups based on body surface area (BSA) involvement. Serum IL-5 and IL-31 levels were measured by Chemiluminescence Immunoassay (CLIA) and ELISA. The SII was calculated as platelets × neutrophils/lymphocytes. Differences between groups were assessed using non-parametric tests, correlations were analyzed using Spearman's correlation, and predictive performance was evaluated using logistic regression and ROC curves. Five patients underwent longitudinal IL-31 and IL-5 measurement pre-and post-treatment. Results IL-31 and IL-5 levels were significantly raised in BP versus HC (median [Q1-Q3]: IL-5: 2.86 [1.22-7.10] vs. 0.79 [0.65-1.00] pg/mL; IL-31: 103.61 [77.42-146.77] vs. 86.02 [51.49-122.53] pg/mL), with further increases in Sev. versus MM groups (IL-5: 3.84 [1.57-10.63] vs. 1.35 [0.83-2.93] pg/mL; IL-31: 125.99 [91.58-173.85] vs. 65.14 [51.27-85.47] pg/mL). Post-treatment IL-31 decreased significantly in 5 patients (145.95±44.25 vs. 108.62±33.45 pg/mL). IL-5, IL-31, and SII positively correlated with BSA (r = 0.458, 0.544, 0.418). Logistic regression analysis identified elevated levels of IL-5, IL-31, and SII as risk factors for the exacerbation of BP disease. ROC analysis demonstrated the remarkable predictive capacity of IL-5, IL-31, and SII for BP disease severity. Conclusion IL-5, IL-31, and SII are promising biomarkers for assessing and predicting BP severity.

Keywords: Bullous pemphigoid, Interleukin-5, interleukin-31, Systemic immunoinflammatory index, Disease Severity, biomarker, ROC Curve

Received: 02 Jul 2025; Accepted: 26 Sep 2025.

Copyright: © 2025 Zhang, Liu, Hou, Zhao, Hao, Zhang, Tian, Li, Liu, Zhou, Xu, Ren and Haizhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Zhou Haizhou, haizhouzhou@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.